Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**6,8-Diprenylgenistein** is a naturally occurring isoflavonoid structurally related to genistein but distinguished by the presence of two prenyl groups at positions 6 and 8. It has been isolated from several plants including Cudrania tricuspidata and Glycyrrhiza uralensis. This compound exhibits multiple biological activities such as antimicrobial effects against both Gram-negative and Gram-positive bacteria and anti-obesity effects demonstrated in high-fat diet-induced obese mice. Mechanistically in cancer models it inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis by suppressing VEGF-A/VEGFR2 signaling pathways (including FAK/PI3K/AKT/p38/ERK) as well as hypoxia-inducible factor HIF1α expression[1][3][4][5]. Its primary research applications are in metabolic disease (obesity), infection control (antibacterial), and cancer metastasis prevention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6,8-diprenylgenistein.